New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
04:55 EDTBAX, BAX, BAX, LH, LH, LH, ACT, ACT, ACT, HUM, HUM, HUM, UNH, UNH, UNH, THOR, THOR, THOR, HSIC, HSIC, HSIC, VRTX, VRTX, VRTX, CNC, CNC, CNC, BSX, BSX, BSX, HNT, HNT, HNTBarclays to hold a conference
Healthcare Conference is being held in Miami, Florida on March 11-13.
News For BAX;BSX;CNC;VRTX;HSIC;THOR;UNH;HUM;ACT;LH;HNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 18, 2015
12:24 EDTBAXBaxter sees FY16 sales growth 2%-3%
Subscribe for More Information
12:20 EDTBAXBaxter sees 2H sales growth approximately flat in constant currency
Subscribe for More Information
11:21 EDTACTAckman sold out of Actavis stake after Q1 report, NY Post says
Subscribe for More Information
08:46 EDTLHLabCorp announces full portfolio of Hep C virus drug resistance assays
LabCorp announced the launch of two new Hepatitis C Virus drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorp’s portfolio of HCV resistance tests that includes HCV GenoSure NS3/4A, which was launched in 2011. These tests are available through Monogram Biosciences, a member of the LabCorp Specialty Testing Group, and a leader in the development and commercialization of innovative antiviral diagnostics.
08:39 EDTBAXBaxter says Baxalta separation on-track for mid-year 2015
Subscribe for More Information
08:01 EDTACTActavis launches Namzaric to treat moderate to severe Alzheimer's
Actavis announced that NAMZARIC, a once-daily, fixed-dose combination of memantine hydrochloride extended-release, and donepezil hydrochloride, is now available to patients and healthcare professionals across the United States. NAMZARIC was approved by the FDA in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
07:22 EDTACTUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
07:15 EDTACTPhysician feedback on Actavis Eluxadoline positive, says RBC Capital
After conducting a survey, RBC Capital says that physician enthusiasm about Actavis' Eluxadoline is high ahead of its expected early 2016 launch. The firm thinks the drug could be an important P&L driver for the company and keeps a Top Pick rating on the shares.
06:58 EDTACTActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
17:31 EDTBAXBaxter gets FDA approval for Spain facility to produce Sodium Chloride Injection
Subscribe for More Information
17:15 EDTACTPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:03 EDTACTPershing Square gives quarterly update on stakes
Subscribe for More Information
14:51 EDTACTMylan ANDA for generic version of Lexapro approved by FDA
The ANDA from Mylan (MYL) for a generic version of Escitalopram Oxalate, which is sold under the trade name Lexapro by Actavis' (ACT) Forest Labs, was approved by the FDA on May 14, according to a post to the regulator's site. Reference Link
12:13 EDTACTThird Point gives quarterly update on stakes
NEW STAKES: Yum! Brands (YUM), NXP Semiconductors (NXPI), FedEx (FDX), McKesson (MCK), and J M Smucker (SJM). INCREASED STAKES: Actavis (ACT), Roper Technologies (ROP), Delta Air Lines (DAL), and FleetCor Technologies (FLT). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Phillips 66 (PSX), eBay (EBAY), and Anheuser Busch Inbev SA (BUD). LIQUIDATED STAKES: Alibaba Group (BABA), Citigroup (C), EMC Corporation (EMC), Anglo American (AAL), and Williams Companies (WMB).
11:08 EDTHUMOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
10:29 EDTBSXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTVRTX, BSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
09:29 EDTACTActavis: Warner Chilcott has held talks with DOJ over sales tactics, WSJ says
Subscribe for More Information
08:30 EDTACTActavis price target raised to $360 from $325 at Susquehanna
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use